Virology
TWiV 914: COVID-19 clinical update #121 with Dr. Daniel Griffin
By Vincent Racaniello
In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and ...
TWiV 911: Antibody can get vaccinated now
By Vincent Racaniello
TWiV provides an update on hepatitis of unknown etiology in children, an experimental nanoparticle vaccine for Epstein-Barr virus, and minimal impact of bamlanivimab therapy on antiviral antibodies induced by vaccination. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Click arrow to playDownload TWiV 911 (76 MB .mp3, 127 min)Subscribe (free): Apple ...
TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin
By Vincent Racaniello
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with ...
TWiV 906: Long COVID, giant viruses, and smallish pox
By Vincent Racaniello
TWiV reviews human monkeypox infections, evidence for human Mimivrus infections, and incidence of long COVID in post-vaccine SARS-CoV-2 infections. Become a patron of TWiV! Dickson - Lake Mead water level very lowBrianne - Transplantation of a 3D printed ear made out of human cellsRich - nderstanding Vaccine Safety and the Roles of the ...
TWiV 905: COVID-19 clinical update #117 with Dr. Daniel Griffin
By Vincent Racaniello
In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with ...
